Comparing lengths of tirofiban treatment after clot-busting therapy
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests whether giving the blood-thinning drug tirofiban for a shorter or longer time after standard clot-busting treatment improves recovery from a stroke. It aims to find the best duration to prevent further damage while avoiding side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You had a stroke caused by a blocked blood vessel and received clot-busting medication (tenecteplase, alteplase, or reteplase).
- Between 2 and 24 hours after the clot-busting treatment, you still have noticeable disability, like weakness in an arm or leg.
- You cannot join if a scan shows bleeding in the brain, or if you have a large blocked artery, certain heart conditions, or severe kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether starting tirofiban soon after tenecteplase can improve outcomes for people whose stroke symptoms temporarily get worse after treatment. It aims to see if the added medicine can reduce harmful clot-related changes after initial thrombolysis.
This trial tests whether giving tirofiban (a blood thinner) shortly after the standard clot-busting drug tenecteplase can improve recovery from a moderate stroke. It is for people who have had a stroke within the last few hours and do not have certain risk factors like irregular heart rhythm or recent bleeding.
This trial tests a medication called tirofiban given intravenously after standard thrombolysis to see if it improves recovery in people with acute ischemic stroke. It is for those whose symptoms have not improved or are getting worse after initial treatment.
This trial tests whether giving a medication called tirofiban directly into the artery (intra-arterially) after a successful clot removal can improve recovery after a stroke. Tirofiban helps prevent new clots from forming, which may reduce the chance of another stroke.
This trial tests whether adding a second medicine (tirofiban) to standard clot-busting treatment can help people who are not improving after the first hour. It is for people with a moderate to severe stroke who are not candidates for a clot-removal procedure.
This trial tests adding the anti-clotting drug tirofiban to standard clot removal for people who have a stroke due to a narrowed artery in the brain. The goal is to see if this combination improves outcomes without raising bleeding risk.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.